Skip to content

Author

Tong-Mei Zhang

6 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Bone Metastasis and the Immunosuppressive Tumor Microenvironment: Mechanisms and Therapeutic Strategies

Numerous solid tumours have bone as one of their most common sites of distant metastasis, and bone metastasis causes skeletal-related events (SREs) that impair quality of life and portend poor prognosis. Bone metastasis arises not from invasive tumour cells alone but through mutual adaptation and co-evolution between t...

M. Ba, Yu-Zhu Chen, Peng Jiang et al. · 0 citations
Review Open access Aug 2026

Extracellular Matrix Stiffness Regulates Mechanical-Metabolic Coupling in Tumors: Mechanisms and Therapeutic Opportunities.

The extracellular matrix (ECM) stiffening in the tumor microenvironment (TME) is an important physical characteristic of solid tumors and can serve as an active signaling hub that regulates the biological behavior of tumors. Abnormal deposition, cross-linking, and remodeling of collagen not only alter the mechanical pr...

Xiao-Lin Liu, Ying Wang, Fei Qi et al. · 0 citations
Open access Oct 2026

MAGI3 Acts as an Intestinal Epithelial Gatekeeper in Inflammation‐Associated Colorectal Cancer by Suppressing the STAT3‐CCL2 Axis and TAM‐Mediated Immunosuppression

ABSTRACT Chronic intestinal inflammation is a major driver of colorectal cancer (CRC). As the mucosal barrier's frontline sentinel, the intestinal epithelium initiates the inflammation‐to‐cancer transition. However, the early cell‐intrinsic events that convert inflammatory responses into a sustained pro‐tumorigenic pro...

Yu-Meng Yang, Zhi-Gang Bai, Hai-Bo Wang et al. · 0 citations
Review Oct 2026

Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China.

BACKGROUND Izalontamab brengitecan (iza-bren) is a first-in-class bispecific antibody-drug conjugate targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3) and has shown antitumour activity in EGFR-mutated non-small-cell lung cancer (NSCLC). We compared iza-bren with plati...

Shao-Dong Hong, Ting Zhou, Xue Hou et al. · 0 citations
Open access Sep 2026

The circulating tumor microenvironment in small-cell lung cancer: Vimentin-positive circulating tumor endothelial cells as drivers of metastasis and poor prognosis in a large cohort study.

Investigation of the critical role of CD31+ aneuploid circulating tumor endothelial cells expressing vimentin in promoting SCLC metastasis concluded that Vim+ CTECs serve as a key driver of tumor metastasis in SCLC.

Ying Wang, Fei Qi, Ming-Hang Zhang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.